Form 4: Incyte EVP Sells Shares Under 10b5-1 Plan

Incyte's EVP & Chief Medical Officer, Steven H. Stein, sold a total of 22,664 shares of common stock and had 17,093 shares withheld for taxes in early December 2025, pursuant to a Rule 10b5-1 plan.

Summary

• Steven H. Stein, Executive Vice President and Chief Medical Officer of Incyte Corp (INCY), reported transactions involving the company's common stock.
• On December 1, 2025, Mr. Stein sold 2,559 shares of common stock at a price of $102.96 per share.
• Also on December 1, 2025, 17,093 shares were withheld by the Issuer to satisfy tax withholding obligations related to the settlement of previously reported Restricted Stock Units (RSUs) or earned performance shares, at a price of $102.04 per share.
• On December 2, 2025, Mr. Stein sold an additional 20,105 shares of common stock at a price of $102.51 per share.
• All reported transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.
• Following these transactions, Mr. Stein beneficially owns 63,129 shares of common stock, which includes 63,129 shares issuable pursuant to previously reported unvested restricted stock units and earned performance shares.

Sentiment

Score: 5

Explanation: The transactions represent routine, pre-scheduled sales and tax withholdings under a Rule 10b5-1 plan, which are generally not indicative of a change in management's sentiment regarding the company's prospects.

Stakeholder Impact

• Shareholders: Routine insider sales under a 10b5-1 plan typically have minimal direct impact on shareholder sentiment or company valuation, as they are pre-scheduled and not necessarily reflective of new information.

Key Dates

Keywords

Incyte, INCY, insider trading, Form 4, stock sale, 10b5-1 plan, executive compensation, biopharmaceutical